BACKGROUND: Chronic liver diseases are common in the general population. Drug treatment in this group may be challenging, as many drugs are hepatically metabolised and hepatotoxic. OBJECTIVES: We aimed to assess the mortality of patients with chronic liver disease according to specific drug exposures and the three laboratory parameters creatinine, bilirubin and International Normalised Ratio (INR). METHODS: We conducted a multicentre, 5-year retrospective cohort study in two tertiary university referral hospitals and a secondary referral hospital, using a research database to evaluate the crude and adjusted mortality. RESULTS: Of 1159362 individual patients 1.7% (n = 20158) had chronic liver disease and in this group 36.8% had unspecified chronic non-alcoholic liver disease, 30.1% chronic hepatitis C and 11.9% cirrhosis of the liver. 8.4% of patients presented a diagnosis associated with alcohol. The 4-year survival rates were significantly higher in the group with the most normal laboratory values (94.3%) versus 34.5% in the group with elevated parameters (p <0.001). Overall, drug exposure was not associated with higher mortality; in adjusted multivariate analysis the hazard ratio for anti-cancer drugs was 2.69 (95% CI 1.32-5.46). Of individual drugs, mortality hazard ratios for amiodarone, morphine oral, acetazolamide, sirolimus and lamivudine were 2.46 (95% CI 1.68-3.61), 2.26 (95% CI 1.78-2.86), 2.10 (95% CI 1.19-3.70), 1.81 (95% CI 1.02-3.21) and 1.72 (95% CI 1.17-2.53) respectively. CONCLUSIONS: Drug exposure in general was not associated with higher mortality except for a few categories. Mortality in patients with chronic liver disease was high and is associated with simple laboratory values.
BACKGROUND: Chronic liver diseases are common in the general population. Drug treatment in this group may be challenging, as many drugs are hepatically metabolised and hepatotoxic. OBJECTIVES: We aimed to assess the mortality of patients with chronic liver disease according to specific drug exposures and the three laboratory parameters creatinine, bilirubin and International Normalised Ratio (INR). METHODS: We conducted a multicentre, 5-year retrospective cohort study in two tertiary university referral hospitals and a secondary referral hospital, using a research database to evaluate the crude and adjusted mortality. RESULTS: Of 1159362 individual patients 1.7% (n = 20158) had chronic liver disease and in this group 36.8% had unspecified chronic non-alcoholic liver disease, 30.1% chronic hepatitis C and 11.9% cirrhosis of the liver. 8.4% of patients presented a diagnosis associated with alcohol. The 4-year survival rates were significantly higher in the group with the most normal laboratory values (94.3%) versus 34.5% in the group with elevated parameters (p <0.001). Overall, drug exposure was not associated with higher mortality; in adjusted multivariate analysis the hazard ratio for anti-cancer drugs was 2.69 (95% CI 1.32-5.46). Of individual drugs, mortality hazard ratios for amiodarone, morphine oral, acetazolamide, sirolimus and lamivudine were 2.46 (95% CI 1.68-3.61), 2.26 (95% CI 1.78-2.86), 2.10 (95% CI 1.19-3.70), 1.81 (95% CI 1.02-3.21) and 1.72 (95% CI 1.17-2.53) respectively. CONCLUSIONS: Drug exposure in general was not associated with higher mortality except for a few categories. Mortality in patients with chronic liver disease was high and is associated with simple laboratory values.
Authors: Sadeq A Quraishi; Augusto A Litonjua; Kevin M Elias; Fiona K Gibbons; Edward Giovannucci; Carlos A Camargo; Kenneth B Christopher Journal: Br J Nutr Date: 2015-06-14 Impact factor: 3.718
Authors: Kris M Mogensen; Clare M Horkan; Steven W Purtle; Takuhiro Moromizato; James D Rawn; Malcolm K Robinson; Kenneth B Christopher Journal: JPEN J Parenter Enteral Nutr Date: 2017-12-18 Impact factor: 4.016
Authors: Sadeq A Quraishi; Augusto A Litonjua; Takuhiro Moromizato; Fiona K Gibbons; Carlos A Camargo; Edward Giovannucci; Kenneth B Christopher Journal: JPEN J Parenter Enteral Nutr Date: 2014-02-03 Impact factor: 4.016
Authors: Torrey Boland; Galen V Henderson; Fiona K Gibbons; H Bart Brouwers; Steven M Greenberg; Miriam Raffeld; Christina E Kourkoulis; Jonathan Rosand; Kenneth B Christopher Journal: Neurocrit Care Date: 2016-08 Impact factor: 3.210
Authors: Sadeq A Quraishi; Augusto A Litonjua; Takuhiro Moromizato; Fiona K Gibbons; Carlos A Camargo; Edward Giovannucci; Kenneth B Christopher Journal: Am J Clin Nutr Date: 2013-08-14 Impact factor: 7.045
Authors: Christin Edmark; Mark J W McPhail; Max Bell; Tony Whitehouse; Julia Wendon; Kenneth B Christopher Journal: Intensive Care Med Date: 2016-01-28 Impact factor: 17.440